Company Overview of Phenomix Corporation
On October 26, 2010, Phenomix Corporation went out of business. Phenomix Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of small-molecule product candidates. Its product candidate includes PHX1149, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. The company's product candidate also includes PHX1766, which is a protease inhibitor for the treatment of hepatitis C virus infection. It focuses its small-molecule drug discovery efforts on enzyme targets, including proteases, kinases, and polymerases. Phenomix Corporation was founded in 2001 and is headquartered in San Diego, California.
5930 Cornerstone Court West
San Diego, CA 92121
Founded in 2001
Key Executives for Phenomix Corporation
Phenomix Corporation does not have any Key Executives recorded.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Phenomix Corporation, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.